Average Insider

Where insiders trade, we follow

$NRIX
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Healthcare
Sector
Biotechnology
Industry
Arthur T. Sands
CEO
286
Employees
$15.95
Current Price
$1.34B
Market Cap
52W Low$11.67
Current$15.9525.8% above low, 74.2% below high
52W High$28.23

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00--All Sells
Sells23$232,478.8810,882
1 monthBuys00--All Sells
Sells39$827,827.6233,684
2 monthsBuys00--All Sells
Sells412$1,526,804.6263,505
3 monthsBuys00--All Sells
Sells415$1,712,859.4170,744
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Nov 4, 2026
van Houte Hans
Chief Financial Officer
Sale1,469$16.20$23,800.44View Details
Nov 4, 2026
van Houte Hans
Chief Financial Officer
Sale3,300$15.38$50,761.92View Details
Nov 3, 2026
Ring Christine
Chief Legal Officer
Sale6,113$25.83$157,916.52View Details
Nov 2, 2026
Ring Christine
Chief Legal Officer
Sale9,527$25.74$245,217.36View Details
Nov 2, 2026
Ring Christine
Chief Legal Officer
Sale1,075$26.76$28,770.01View Details
Oct 30, 2026
van Houte Hans
Chief Financial Officer
Sale2,834$26.28$74,474.97View Details
Oct 30, 2026
Ring Christine
Chief Legal Officer
Sale3,957$26.28$103,986.40View Details
Oct 30, 2026
Hansen Gwenn
Chief Scientific Officer
Sale3,957$26.28$103,986.40View Details
Nov 2, 2026
Hansen Gwenn
Chief Scientific Officer
Sale1,452$26.80$38,913.60View Details
Oct 15, 2026
Hansen Gwenn
Chief Scientific Officer
Sale1,452$25.00$36,300.00View Details
Oct 14, 2026
GREGORY JULIA P
Director
Sale22,583$23.40$528,528.02View Details
Oct 2, 2026
Ring Christine
Chief Legal Officer
Sale5,786$23.19$134,148.99View Details
Sep 2, 2026
Ring Christine
Chief Legal Officer
Sale400$26.64$10,655.00View Details
Sep 2, 2026
Ring Christine
Chief Legal Officer
Sale5,387$25.69$138,417.35View Details
Sep 1, 2026
Hansen Gwenn
Chief Scientific Officer
Sale1,452$25.47$36,982.44View Details
33 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Oct 8, 2026
EPS
Estimated-$0.60
ActualN/A
Revenue
Estimated$24.35M
ActualN/A
4 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.10.12